680591-13-3

Usage

Uses

Used in Pharmaceutical Industry:
Benzenesulfonamide, N-(6-methoxy-3-pyridinyl)-2-methyl-, is used as an intermediate in the synthesis of potential PET (positron emission tomography) tracers for orexin 2 receptors. This application is significant in the development of diagnostic tools for neurological disorders and conditions related to the orexin system, such as narcolepsy and addiction.

Upstream product

• 6628-77-9 6-methoxy-pyridin-3-ylamine 
• 133-59-5 Toluene-2-sulfonyl chloride 

Downstream Products

• 680591-44-0 [(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-acetic acid 
• 680590-49-2 [3H]-EMPA 
• 1435913-07-7 C₂₂H₂₄N₄O₄S 

Relevant academic research and scientific papers

SULFONAMIDES DERIVATIVES AS URAT1 INHIBITORS

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a sulfonamide URAT1inhibitor of formula (I), or a pharmaceutically acceptable salt thereof for use as a medicament, wherein R1, X1 and m as defined in the description, and to certain new sulfonamide URAT1 inhibitors. URAT1 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly gout.

Radiosynthesis and evaluation of [11C]EMPA as a potential PET tracer for orexin 2 receptors

EMPA is a selective antagonist of orexin 2 (OX2) receptors. Previous literature with [3H]-EMPA suggest that it may be used as an imaging agent for OX2 receptors; however, brain penetration is known to be modest. To evaluate the potential of EMPA as a PET radiotracer in non-human primate (as a step to imaging in man), we radiolabeled EMPA with carbon-11. Radiosynthesis of [11C]N-ethyl-2-(N-(6-methoxypyridin-3- yl)-2-methylphenylsulfonamido)-N-(pyridin-3-ylmethyl)acetamide ([ 11C]EMPA), and evaluation as a potential PET tracer for OX 2 receptors is described. Synthesis of an appropriate non-radioactive O-desmethyl precursor was achieved from EMPA with sodium iodide and chlorotrimethylsilane. Selective O-methylation using [11C]CH 3I in the presence of cesium carbonate in DMSO at room temp afforded [11C]EMPA in 1.5-2.5% yield (non-decay corrected relative to trapped [11C]CH3I at EOS) with ≥95% chemical and radiochemical purities. The total synthesis time was 34-36 min from EOB. Studies in rodent suggested that uptake in tissue was dominated by nonspecific binding. However, [11C]EMPA also showed poor uptake in both rats and baboon as measured with PET imaging.

AMINOETHANE SULFONAMIDE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to aminoethane sulfonamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are invo

SULFONYLAMINO-ACETIC ACID DERIVATIVES

The invention relates to novel sulfonylamino-acetic acid derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.